



# Twenty-Four-Hour Central (Aortic) Systolic Blood Pressure: Reference Values and Dipping Patterns in Untreated Individuals

Thomas Weber<sup>1</sup>, Athanase D. Protogerou, Mohsen Agharazii, Antonis Argyris<sup>2</sup>, Sola Aoun Bahous, Jose R. Banegas<sup>3</sup>, Ronald K. Binder, Jacques Blacher, Andréa Araujo Brandao, Juan J. Cruz, Kathrin Danninger, Cristina Giannatasio, Auxiliadora Graciani, Bernhard Hametner<sup>4</sup>, Piotr Jankowski<sup>5</sup>, Yan Li, Alessandro Maloberti<sup>6</sup>, Christopher C. Mayer, Barry J. McDonnell<sup>7</sup>, Carmel M. McEniery, Marco Antonio Mota Gomes<sup>8</sup>, Annelise Machado Gomes<sup>9</sup>, Maria Lorenza Muiesan<sup>10</sup>, Janos Nemcsik, Anna Paini, Enrique Rodilla, Aletta E. Schutte, Petros P. Sfikakis, Dimitrios Terentes-Printzios<sup>11</sup>, Alexandre Vallée, Charalambos Vlachopoulos<sup>12</sup>, Lisa Ware, Ian Wilkinson, Robert Zweiker, James E. Sharman<sup>13</sup>, Siegfried Wassertheurer; International Academic 24-Hour Ambulatory Aortic Blood Pressure Consortium (i24abc.org)

**ABSTRACT:** Central (aortic) systolic blood pressure (cSBP) is the pressure seen by the heart, the brain, and the kidneys. If properly measured, cSBP is closer associated with hypertension-mediated organ damage and prognosis, as compared with brachial SBP (bSBP). We investigated 24-hour profiles of bSBP and cSBP, measured simultaneously using Mobilograph devices, in 2423 untreated adults (1275 women; age, 18–94 years), free from overt cardiovascular disease, aiming to develop reference values and to analyze daytime-nighttime variability. Central SBP was assessed, using brachial waveforms, calibrated with mean arterial pressure (MAP)/diastolic BP (cSBP<sub>MAP/DBPcal</sub>), or bSBP/diastolic blood pressure (cSBP<sub>SBP/DBPcal</sub>), and a validated transfer function, resulting in 144 509 valid brachial and 130 804 valid central measurements. Averaged 24-hour, daytime, and nighttime brachial BP across all individuals was 124/79, 126/81, and 116/72 mmHg, respectively. Averaged 24-hour, daytime, and nighttime values for cSBP<sub>MAP/DBPcal</sub> were 128, 128, and 125 mmHg and 115, 117, and 107 mmHg for cSBP<sub>SBP/DBPcal</sub>, respectively. We pragmatically propose as upper normal limit for 24-hour cSBP<sub>MAP/DBPcal</sub> 135 mmHg and for 24-hour cSBP<sub>SBP/DBPcal</sub> 120 mmHg. bSBP dipping (nighttime-daytime/daytime SBP) was −10.6 % in young participants and decreased with increasing age. Central SBP<sub>SBP/DBPcal</sub> dipping was less pronounced (−8.7% in young participants). In contrast, cSBP<sub>MAP/DBPcal</sub> dipping was completely absent in the youngest age group and less pronounced in all other participants. These data may serve for comparison in various diseases and have potential implications for refining hypertension diagnosis and management. The different dipping behavior of bSBP versus cSBP requires further investigation. (**Hypertension**. 2022;79:251–260. DOI: 10.1161/HYPERTENSIONAHA.121.17765.) • **Supplemental Material**

**Key Words:** arterial pressure ■ blood pressure ■ heart rate ■ hypertension

Whereas mean arterial pressure (MAP) and diastolic blood pressure (DBP) are relatively constant along the arterial tree, the height of the pressure pulse is amplified from the aorta toward peripheral arteries.<sup>1</sup> Therefore, central systolic blood pressure

(cSBP), usually defined as aortic or carotid SBP, differs from brachial SBP (bSBP). When measured simultaneously and invasively at both sites, brachial systolic pressures are higher than aortic pressures to a certain amount.<sup>1</sup> This so-called pressure amplification is highly

Correspondence to: Thomas Weber, Cardiology Department, Klinikum Wels-Grieskirchen, Grieskirchnerstrasse 42, 4600 Wels, Austria. Email thomas.weber3@liwest.at  
The Supplemental Material is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.121.17765>.

For Sources of Funding and Disclosures, see page 258.

© 2021 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

*Hypertension* is available at [www.ahajournals.org/journal/hyp](http://www.ahajournals.org/journal/hyp)

## Novelty and Significance

### What Is New?

- Reference values for 24-hour cSBP from a worldwide research consortium are now available.

### What Is Relevant?

- These reference values may facilitate the clinical adoption of cSBP, particularly its 24-hour measurement. Furthermore, the different dipping behavior of central versus brachial SBP requires further study,

pertaining to its physiological and pathophysiological consequences.

### Summary

Derived from a research consortium (20 centers, 14 countries, and 5 continents), using 130804 valid cSBP measurements in 2423 untreated adults, we pragmatically propose as upper normal limit for 24-hour cSBP<sub>MAP/DBPcal</sub> 135 mmHg and for 24-hour cSBP<sub>SBP/DBPcal</sub> 120 mmHg.

## Nonstandard Abbreviations and Acronyms

<b>bSBP</b>	brachial systolic blood pressure
<b>cSBP</b>	central systolic blood pressure
<b>DBP</b>	diastolic blood pressure
<b>i24abc</b>	International 24-Hour Ambulatory Aortic Blood Pressure Consortium
<b>MAP</b>	mean arterial pressure

variable between individuals and is the consequence of the progressive reduction of diameter and increase in stiffness from the proximal to the distal arterial vessels and the impact of wave reflections.<sup>2</sup> Clinically, the amount of amplification depends on age, sex, heart rate, body height, and cardiovascular risk factors (eg, dyslipidemia, diabetes, and smoking).<sup>3</sup>

As vital organs such as the brain, the heart, and the kidneys are exposed to central (aortic) rather than brachial pressures, central BP is pathophysiologically more relevant.<sup>2,4</sup> Indeed, cSBP is more closely related to hypertension-mediated organ damage such as left ventricular hypertrophy, intima-media thickness, and pulse wave velocity.<sup>5</sup> In many,<sup>6–9</sup> but not all<sup>10</sup> longitudinal studies, central pressures were better predictors of cardiovascular events, as compared with brachial pressures. Finally, interventional studies have established the concept that antihypertensive drug treatment may have different effects on bSBP and cSBP.<sup>11–14</sup> In a randomized trial,<sup>15</sup> guidance of hypertension management with central BP resulted in a significantly different therapeutic pathway than conventional brachial BP and resulted in less use of medication to achieve BP control, with no adverse effects on left ventricular mass, aortic stiffness, or quality of life.

From a technical point of view, noninvasive determination of cSBP is most commonly achieved by the acquisition of peripheral (radial or brachial) waveforms, calibration of the waveforms using brachial BP, and application of dedicated mathematics (mostly, so-called transfer formulae)

to derive the central BP curve.<sup>16</sup> Waveform calibration is the critical aspect here, due to the well-established systematic underestimation of true (ie, invasive) bSBP by noninvasive cuff-based measurement,<sup>17</sup> which seems to be based on the inability of the first Korotkoff sound to determine bSBP correctly.<sup>18</sup> Consequently, waveform calibration with noninvasive cuff-based SBP (and DBP) will most often result in underestimation of cSBP, as compared with true (ie, actual as measured invasively) cSBP, albeit with preservation of SBP amplification. On the other hand, waveform calibration with MAP (and DBP) can result in a better estimate of true (=invasive) cSBP,<sup>16,19,20</sup> albeit with apparent distortion (ie, negative/inverse) of SBP amplification (apparent relates to the fact that a noninvasive gold standard is used for bSBP and an invasive gold standard is used for cSBP<sub>MAP/DBP-cal</sub>). With respect to the Mobilograph device, one invasive study, using high-fidelity pressure-sensor dipped catheters as reference, in 30 patients has shown that calibration with MAP/DBP provides better estimation of cSBP compared with SBP/DBP calibration.<sup>21</sup> On the contrary, another recent study, which used fluid-filled catheters as reference, but adhered to the Association for Research into Arterial Structure and Physiology Society guidelines, reported wider limits of agreement with MAP/DBP calibration.<sup>22</sup> In any case, clinical superiority of noninvasive MAP/DBP calibrated cSBP has been demonstrated in terms of relationship with coronary atherosclerosis,<sup>23</sup> cardiac structural abnormalities,<sup>24</sup> and prognosis.<sup>25</sup>

In all the aforementioned studies, office-based BP measurements were used. As far as brachial BP is concerned, 24-hour ambulatory BP is a stronger predictor of cardiovascular events,<sup>26</sup> all-cause mortality, and cardiovascular mortality than office BP.<sup>26</sup> Nighttime BP and nighttime/daytime difference (dipping) have been of particular value<sup>26</sup> in aiding cardiovascular risk prediction. With technological progress, measurement of cSBP during 24-hour ambulatory monitoring is now possible, using brachial cuff-based devices.<sup>21,27,28</sup> Accordingly, 24-hour cSBP was closer associated with left ventricular mass/hypertrophy<sup>29,30</sup> and diastolic dysfunction,<sup>31</sup> as compared

with 24-hour bSBP. Again, the advantage of cSBP over bSBP was dependent on technical aspects, favoring the MAP/DBP calibration method.

So far, despite the growing clinical evidence, reference values for 24-hour cSBP, based on large, multinational samples, are currently missing. Moreover, the circadian variability of BP amplification<sup>32</sup> and, closely related, the nighttime/daytime variability of cSBP versus bSBP have been poorly studied. To address these issues, we established a global academic research network (i24abc [International 24-Hour Ambulatory Aortic Blood Pressure Consortium]), aiming to derive reference standards for 24-hour ambulatory cSBP, using a widely available validated oscillometric device.

## METHODS

### Study Organization and Participants

Researchers were invited through personal contact, announcements at conferences, and the project website ([www.i24abc.org](http://www.i24abc.org)) to contribute to the consortium with existing study data, local ethics committee approval, and local written informed consent complying with the Declaration of Helsinki being a prerequisite. A list of contributors is shown in the [Supplemental Material](#). The consortium itself obtained approval from the Tasmanian Health and Medical Human Research Ethics Committee Tasmania (H0015062). The i24abc consortium is an exclusively academic research undertaking, without any influence or financial support from the device manufacturer. For the current analysis, participants without overt cardiovascular disease or diabetes and free from antihypertensive drugs were selected, originating from 21 centers in 14 countries and 5 continents.

Variables used for analysis as well as the inclusion and exclusion criteria were collected systematically at each center and were drawn from medical records or from standardized measurement according to international guidelines of cardiovascular prevention, as appropriate.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### Measurements

Twenty-four-hour ambulatory BP monitoring was performed in all study participants with an identical automated brachial oscillometric device (Mobilograph PWA; IEM, Stolberg, Germany), following published recommendations.<sup>33</sup> The device has been validated in adults for 24-hour heart rate,<sup>34</sup> for brachial BP measurement according to recommendations of the British Hypertension Society<sup>35</sup> and the European Society of Hypertension,<sup>36</sup> for 24-hour brachial BP monitoring<sup>37</sup> against a widely used device, and has received clearance from the US Food and Drug Administration and bears the Conformité Européenne mark. The algorithm for assessment of cSBP with the device has been published and validated invasively against high-fidelity pressure measurements<sup>21</sup> and fluid-filled catheter-based measurements.<sup>38,39</sup> Noninvasive comparisons have been performed in European,<sup>21,39,40</sup> Asian,<sup>38,41</sup> and Latin American<sup>42</sup> populations. Briefly, immediately after the conventional brachial oscillometric BP measurement, pulse waves are recorded, using the brachial

cuff, at DBP level for  $\approx 10$  seconds. After digitalization, a 3-step quality control algorithm is applied.<sup>21</sup> Next, the recorded brachial pulse wave is calibrated with measured brachial BP. With this device, either bSBP/DBP or MAP/DBP can be used for waveform calibration, and the calibration method can be switched post hoc from the raw data. With the device used, MAP/DBP calibration provides cSBP shown to be (1) closer to invasive pressures<sup>16,21,38</sup> in several studies and (2) closer to hypertension-mediated organ damage<sup>29–31</sup> because oscillometric MAP can be measured using this device.<sup>21,43</sup> Thereafter, an aortic pulse waveform is generated by means of a generalized transfer function, and cSBP can be directly read as the maximum of the pulse wave. Their modulus and phase characteristics have been published.<sup>40</sup> Regarding ambulatory measurements with the device, the reproducibility and the feasibility have been confirmed.<sup>27,28</sup>

### Data Handling and Statistics

Raw data from all measurements from all sites were anonymized and sent to the Austrian Institute of Technology, Vienna, Austria, to construct the database. Raw pulse waveforms underwent a 3-step quality control as published previously.<sup>21</sup> Homogenous spreadsheets were returned to study sites to enter available clinical characteristics and finally added to the database.

Participants were divided into 6 age groups (18–29, 30–39, 40–49, 50–59, 60–69, and 70–94 years). Results stratified per sex are shown as 24-hour, daytime, and nighttime means (SD) after testing normal distribution with the Kolmogorov-Smirnov test. Values between sexes were compared with the *t* test, values across age groups were compared using the Kruskal-Wallis ANOVA. Twenty-four-hour profiles were constructed, according to the age groups.

We calculated the threshold values for cSBP following to the approach of Head et al<sup>44</sup>: a least product regression between bSBP and cSBP values was performed to obtain a linear regression equation. Subsequently, the central thresholds were obtained by inserting the brachial thresholds into this equation (and rounding the result to the nearest multiple of 5). The thresholds for bSBP were based on the most recent version of the ESC/ESH guidelines,<sup>45</sup> that is, 130, 135, and 120 mm Hg for 24-hour, daytime, and nighttime bSBP, respectively.

In the absence of patient's diaries for the entire cohort, and based on previous recommendations,<sup>46</sup> nighttime/daytime difference (dipping) was defined as nighttime (01:00–06:00) minus daytime (09:00–21:00) values, either in absolute values or as a percentage of daytime SBP. Determinants of percentage nighttime/daytime difference were calculated with multiple linear regression, including as independent variables those that were clinically relevant a priori: age, sex, BMI, daytime values, and heart rate dipping. SBP amplification was defined as bSBP minus cSBP with either calibration method, keeping in mind that this will result in true amplification with SBP/DBP calibration and in apparent amplification with MAP/DBP calibration.<sup>19</sup> Statistical testing was performed with the MedCalc software, version 13.02 (Maria Kerke, Belgium).

## RESULTS

We included 2423 participants (1275 women) without overt cardiovascular disease or diabetes and free from antihypertensive drugs, from 21 centers worldwide (Table

S1 in the [Supplemental Material](#)). Mean age was 51.9 (SD, 15.3; range, 18–94) years. Mean body mass index was 26.5 (SD, 4.4) kg/m<sup>2</sup>. Of 168 512 BP measurements performed, 144 509 bSBP measurements and 130 804 cSBP measurements were valid and used for the analysis.

### Brachial and Central (Aortic) Blood Pressure

In the entire group, average 24-hour bSBP was 124 mmHg, average 24-hour cSBP<sub>MAP/DBPcal</sub> was 128 mmHg, and average 24-hour cSBP<sub>SBP/DBPcal</sub> was 115 mmHg. Percentiles of average 24-hour, daytime, and nighttime cSBP with both calibration methods are shown in Figure 1 and Figure S1 in the [Supplemental Material](#). Average 24-hour DBP was 79 mmHg, average MAP was 99 mmHg, and average 24-hour heart rate was 72 bpm. Across all age groups, the average value of 24-hour bSBP was in the normotensive range. As expected, 24-hour cSBP<sub>MAP/DBPcal</sub> was slightly higher and 24-hour cSBP<sub>SBP/DBPcal</sub> was lower than bSBP (Table 1; Table S2). Age- and sex-stratified values for MAP, DBP, and heart rate are shown in Table S3.

In a subgroup of 871 participants, average 24-hour bSBP/DBP was below 130/80 mmHg, average daytime bSBP/DBP was below 135/85 mmHg, and average nighttime bSBP/DBP was below 120/70 mmHg, respectively (Table 2). In this true normotensive group, average 24-hour/daytime/nighttime bSBP was 115/118/104 mmHg, respectively, and the 90th percentile of 24-hour/daytime/nighttime bSBP was 124/128/114 mmHg. In this subgroup, the 90th percentile of average 24-hour/daytime/nighttime cSBP<sub>MAP/DBPcal</sub> was 132/133/130 mmHg, respectively, and the 90th percentile of average 24-hour/daytime/nighttime cSBP<sub>SBP/DBPcal</sub> was 114/118/106 mmHg, respectively.

Based on the mean values of the entire group and the 90th percentiles of the truly normotensive group,


the results of our regressions, and taking an upper normal limit of average 24-hour bSBP of 130 mmHg into account,<sup>45</sup> we propose an upper normal limit for average 24-hour cSBP<sub>MAP/DBPcal</sub> to be 135 mmHg and an upper normal limit for average 24-hour cSBP<sub>SBP/DBPcal</sub> to be 120 mmHg. Based on similar considerations, the upper normal limit for daytime and nighttime cSBP<sub>MAP/DBPcal</sub> is proposed to be 140 and 135 mmHg, respectively, and the upper normal limit for daytime and nighttime cSBP<sub>SBP/DBPcal</sub> is proposed to be 125 and 115 mmHg, respectively (Table 2).

### Twenty-Four-Hour Profiles of Brachial and cSBP

bSBP was lower during nighttime than during daytime in all age groups (Figure 2; Table 3), and bSBP dipping decreased with increasing age (Table 3; Figure S2). Both effects were also seen for cSBP<sub>SBP/DBPcal</sub> although absolute values of dipping were slightly lower in younger and middle age and approached those from bSBP in older age groups. In strong contrast, for cSBP<sub>MAP/DBPcal</sub> there was virtually no dipping in the youngest age and an increasing albeit small amount of nocturnal BP fall toward middle age groups that was attenuated again in the elderly (Figure S2).

### Determinants of Nighttime/Daytime Difference (Dipping) of bSBP and cSBP

In multivariable models, the dipping of bSBP was mainly and directly related to heart rate dipping, which alone explained one-quarter of the variability of bSBP dipping (partial *r*, 0.504). Other contributors were daytime bSBP (inversely related) and age (Table S4). The degree of dipping of cSBP<sub>SBP/DBPcal</sub> was also mainly related to heart rate dipping and daytime cSBP<sub>SBP/DBPcal</sub>. The dipping of



**Figure 1.** Percentiles of central systolic blood pressure (cSBP; 24-h average values) with 2 calibration methods from age 18 to 94 y. DBP indicates diastolic blood pressure; MAP, mean arterial pressure; and SBP, systolic blood pressure.



**Table 1. Average Values of 24-h, Daytime, and Nighttime Brachial and Aortic Blood Pressures (MAP/DBP and SBP/DBP Calibrations, Stratified by Sex and Age)**

Age group	Years	n	bSBP, mm Hg						cSBP <sub>MAP/DBPcal</sub> mm Hg						cSBP <sub>SBP/DBPcal</sub> mm Hg					
			24 h		Day		Night		24 h		Day		Night		24 h		Day		Night	
			Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Overall	Total	2423	124	12	126	13	116	15	128	13	128	14	125	16	115	12	117	12	109	14
	Men	1148	126	12	129	13	117	14	130	13	131	14	128	15	117	11	119	12	110	14
	Women	1275	122	12	124	13	115	15	125	13	126	13	122	16	114	11	116	12	108	15
18–29	Total	225	121	10	125	11	111	11	126	12	125	13	126	15	111	9	113	10	103	11
	Men	146	123	9	127	10	112	10	129	12	128	12	129	14	112	8	115	9	104	10
	Women	79	118	11	121	12	109	11	119	11	118	11	120	13	108	11	110	11	102	11
30–39	Total	356	124	13	128	14	115	14	126	14	127	14	123	15	115	12	118	13	108	14
	Men	202	128	12	132	13	118	13	131	13	132	13	129	13	118	11	121	12	110	13
	Women	154	119	13	122	13	111	14	119	12	120	13	117	13	112	12	114	13	105	14
40–49	Total	446	126	13	130	13	117	15	128	13	129	13	124	15	118	12	121	12	111	14
	Men	229	127	12	131	12	117	14	130	12	131	12	126	14	119	11	122	11	111	14
	Women	217	125	13	128	14	116	16	125	13	127	14	121	16	117	13	120	13	110	15
50–59	Total	522	126	13	128	14	119	16	129	14	130	14	125	17	118	12	120	12	111	15
	Men	235	128	13	131	14	120	16	133	15	133	15	129	17	120	12	122	13	113	15
	Women	287	124	12	126	13	117	15	127	12	128	12	123	16	116	11	118	12	110	14
60–69	Total	549	123	12	125	12	118	16	129	13	129	14	126	16	114	11	116	11	109	15
	Men	218	124	13	126	13	119	16	130	14	131	15	128	17	115	12	117	12	110	15
	Women	331	122	11	124	12	117	16	128	13	128	13	125	16	113	11	115	11	108	15
70–94	Total	325	120	11	122	11	114	14	127	12	127	12	124	15	111	10	112	10	105	14
	Men	118	119	11	121	11	114	13	128	13	128	13	125	15	109	10	111	10	104	13
	Women	207	121	11	122	11	114	15	127	12	127	12	124	15	111	10	113	10	105	14

Differences between age categories were statistically significant ( $P < 0.001$  for all tests; Kruskal-Wallis ANOVA) for all parameters shown. bSBP indicates brachial systolic blood pressure; cSBP, central systolic blood pressure; DBP, diastolic blood pressure; and MAP, mean arterial pressure.

cSBP<sub>MAP/DBPcal</sub> was mainly and inversely related to daytime cSBP<sub>MAP/DBPcal</sub> and the relationship with heart rate dipping was weak (Figure 3).

### Systolic Blood Pressure Amplification During 24 Hours, Daytime, and Nighttime

With SBP/DBP calibration, 24-hour SBP amplification was relatively stable across all age groups (Table S5; Figure S3). Furthermore, SBP amplification was higher during daytime as compared with nighttime, in particular in younger age, whereas this difference tended to disappear in old age. With MAP/DBP calibration, we


observed an apparently inverse amplification, which was particularly pronounced during nighttime (due to the lack of nighttime dipping of cSBP<sub>MAP/DBPcal</sub> in the presence of nighttime dipping of bSBP). This apparently inverse amplification was more pronounced in younger age (up to 14.6 mmHg) and decreased in middle and older age (to a minimum of 4.1 mmHg; Figure S3).

The nighttime/daytime difference (dipping) of SBP amplification was closely related to the dipping of heart rate:  $r = 0.76$  with MAP/DBP calibration and  $r = 0.42$  with SBP/DBP calibration and thus the main driver of the different dipping patterns of bSBP and cSBP, in particular, cSBP<sub>MAP/DBPcal</sub>.

**Table 2. Proposed Upper Normal Limits for Ambulatory cSBP in 2021\***

	bSBP ESC/ESH GL	bSBP average value all participants current study	bSBP 90th percentile true normotensives* current study	Proposal cSBP <sub>MAP/DBPcal</sub>	cSBP <sub>MAP/DBPcal</sub> average value all participants current study	cSBP <sub>MAP/DBPcal</sub> 90th percentile true normotensives* current study	Proposal cSBP <sub>SBP/DBPcal</sub>	cSBP <sub>SBP/DBPcal</sub> average value all participants current study	cSBP <sub>SBP/DBPcal</sub> 90th percentile true normotensives* current study
24 h	130	124	124	135	128	132	120	115	114
Daytime	135	126	128	140	128	133	125	117	118
Nighttime	120	116	114	130	125	130	115	109	106

True normotensives were defined as average 24-h BP  $< 130/80$  mmHg, average daytime BP  $< 135/85$  mmHg, and average nighttime BP  $< 120/70$  mmHg. BP indicates blood pressure; bSBP, brachial systolic blood pressure; cSBP, central systolic blood pressure; ESC, European Society of Cardiology; ESH, European Society of Hypertension; and GL, guideline.



**Figure 2. Twenty-four-hour profiles of brachial and central systolic blood pressure (cSBP; 2 calibration methods), stratified by age.** Solid lines are mean values, dashed lines 95% CIs. DBP indicates diastolic blood pressure; MAP, mean arterial pressure; and SBP, systolic blood pressure.

### Twenty-Four-Hour Profiles of bSBP and cSBP in Men and Women

In the younger age groups, men had higher BPs, as compared with women (Table 1). The difference was largest with regard to  $cSBP_{MAP/DBP_{cal}}$  and amounted a maximum of 12 mm Hg in individuals 30 to 39 years old. In the older age groups, differences were smaller. Percentiles of average 24-hour, daytime, and nighttime cSBP with both calibration methods are shown in Figures S4 and S5.

### DISCUSSION

In this study, we describe for the first time reference values and 24-hour profiles of cSBP, based on >140 000 individual BP measurements from a worldwide research consortium. We present results for 2 technical options of assessing cSBP, based on different waveform calibration methods. Moreover, our results shed new light on


nighttime/daytime SBP variability (dipping), relating diurnal changes in SBP and heart rate.

Based on brachial 24-hour BP, average systolic values in all age groups were well below 130 mm Hg (121–126 mm Hg), which is the upper limit of normal BP according to the European Society of Cardiology/European Society of Hypertension guidelines.<sup>45</sup> Corresponding 24-hour average cSBP values could, therefore, be assigned as preliminary thresholds, until outcome-based values become available, and would be, rounded for simplification, 135 mm Hg for  $cSBP_{MAP/DBP_{cal}}$  and 120 mm Hg for  $cSBP_{SBP/DBP_{cal}}$  (graphic abstract). In the large Reference Value project<sup>3</sup> for office-based cSBP, data were standardized across different devices and techniques, yielding values roughly equivalent to our SBP/DBP calibration. In that project, the 50th percentile of cSBP of the so-called normal population with high-normal BP (bSBP, 133 mm Hg) was 126 mm Hg in women and 122 mm Hg in men. In a recent analysis, based on

**Table 3. Nighttime to Daytime Difference (Dipping) of Brachial and Central Blood Pressures As Well As Heart Rate, Stratified by Age**

Age group, y	n	bSBP, mm Hg	bSBP, %	cSBP <sub>MAP/DBP<sub>cal</sub></sub> , mmHg	cSBP <sub>MAP/DBP<sub>cal</sub></sub> , %	cSBP <sub>SBP/DBP<sub>cal</sub></sub> , mmHg	cSBP <sub>SBP/DBP<sub>cal</sub></sub> , %	MAP, mm Hg	MAP, %	DBP, mm Hg	DBP, %	Heart rate, bpm	Heart rate, %
18–29	225	–13.5	–10.6	1.0	1.1	–10.1	–8.7	–13.6	–13.5	–13.7	–17.2	–15.7	–19.8
30–39	356	–12.4	–9.5	–3.4	–2.5	–9.8	–8.2	–12.1	–11.4	–11.9	–13.9	–13.5	–16.5
40–49	446	–12.7	–9.6	–5.6	–4.3	–10.2	–8.3	–12.2	–11.2	–11.7	–13.3	–11.9	–14.7
50–59	522	–9.7	–7.2	–5.0	–3.7	–8.3	–6.6	–9.3	–8.5	–9.0	–10.1	–7.4	–9.2
60–69	549	–6.9	–5.3	–2.8	–2.0	–6.5	–5.4	–6.7	–6.6	–6.6	–8.3	–6.7	–8.8
70–94	325	–7.6	–6.1	–2.9	–2.1	–7.3	–6.4	–7.5	–7.7	–7.4	–10.1	–8.4	–11.6

Data are presented either as absolute changes (night-day) or percentage (%) of change (night-day/day). Values across age categories were statistically significant ( $P < 0.001$  for all tests; Kruskal-Wallis ANOVA) for all parameters shown. bSBP indicates brachial systolic blood pressure; cSBP, central systolic blood pressure; DBP, diastolic blood pressure; and MAP, mean arterial pressure.



**Figure 3. Relationship between dipping of heart rate, divided into 4 groups, on the one hand and dipping of brachial systolic blood pressure (bSBP) and central systolic blood pressure (cSBP)<sup>MAP/DBP calibration</sup>, as well as apparent systolic blood pressure (SBP) amplification on the other hand.**

Dipping was calculated as nighttime minus daytime values. Note that dipping of brachial SBP is strongly related to dipping of heart rate, whereas dipping of cSBP<sup>MAP/DBP calibration</sup> is not. DBP indicates diastolic blood pressure; and MAP, mean arterial pressure.

triplicate office-based measurements with the Mobilograph device in 5632 participants with cardiovascular risk factors, mean bSBP was 133 (men) and 135 (women) mmHg, and the corresponding cSBP<sup>SBP/DBPcal</sup> was 125 (men) and 127 (women) mmHg.<sup>47</sup> As 24-hour average BP values are generally lower than office blood pressures, our findings regarding cSBP<sup>SBP/DBPcal</sup> are in good agreement. Similarly, an outcome-based threshold for office cSBP was proposed in a study from Taiwan<sup>48</sup> to be 130 mmHg. Again, in this study, calibration was close to the SBP/DBP method of our work, and given the differences in office- and 24-hour SBP, results were in accordance with our study.

Given the potential of new, cuff-based methods to assess cSBP, a widespread application in clinical routine is conceivable.<sup>49</sup> One potential concern, which has been raised repeatedly, is that cSBP is too highly correlated with bSBP to provide meaningful additional information.<sup>50</sup> Indeed, in a recently reported meta-analysis of cSBP derived from radial tonometry, cardiovascular end points and mortality were not more closely associated with cSBP than bSBP.<sup>51</sup> These findings have been confirmed in a recent, large, population-based study from Canada, where tonometry-derived cSBP was statistically superior to bSBP but with limited additional clinical value in predicting cardiovascular events.<sup>10</sup> Notably, in both studies, cSBP was assessed with SBP/DBP calibration, yielding a correlation between bSBP and cSBP of 0.97. We have addressed this issue earlier for office BP in a more diverse group of 7409 individuals<sup>52</sup> and observed that (1) correlation is close when investigated across the entire spectrum of SBP but much weaker when clinically more relevant BP categories (ie, optimal, normal, high-normal, etc) are taken into account, and (2) correlation with bSBP is closer with cSBP<sup>SBP/DBPcal</sup> as compared

with cSBP<sup>MAP/DBPcal</sup>. We confirmed and extended these findings to average 24-hour SBPs (Table S6), showing for instance a Pearson's correlation coefficient between mean 24-hour bSBP and mean 24-hour cSBP<sup>MAP/DBPcal</sup> in the group of individuals with 24-hour bSBP between 121 and 130 mmHg as low as 0.35, which obviously should allow additive information from cSBP. From a clinical point of view, based on our proposed thresholds for 24-hour cSBP, 149 of 1780 participants would be diagnosed as hypertensive, and 179 of 643 would be diagnosed as normotensive, had cSBP<sup>MAP/DBPcal</sup> instead of bSBP been used for diagnosis.

Nighttime/daytime difference variability (dipping) of BP and heart rate has been long detected, using invasive<sup>53</sup> and noninvasive<sup>54</sup> recordings, and has been attributed to a reduction of responsiveness to external stimuli/change in activity, together with a diminished level of sympathetic nervous activity,<sup>54</sup> and changing to the supine position. Dipping of DBP (14%–17%) is somewhat more pronounced than dipping of (brachial) SBP (10%–12%),<sup>55</sup> as shown in our data set as well. Many, if not most body functions, exhibit clear circadian rhythms,<sup>56</sup> and many among them, including the sympathetic nervous system, body temperature, and kidney function, show a decrease during nighttime. However, these nocturnal changes, for instance in glomerular filtration rate and renal plasma flow, may have only weak associations<sup>57</sup> with systemic hemodynamics and brachial BP. Other measures, such as cerebral blood flow<sup>58</sup> or peripheral subcutaneous blood flow,<sup>59</sup> are even the highest during nighttime but again have only weak if any associations with BP. The probably most intriguing finding of the current study, that is, the absence of nocturnal dipping of cSBP<sup>MAP/DBPcal</sup>, particularly in young individuals, should be viewed within this context.

The strongest determinant of dipping of bSBP was dipping of heart rate, followed by daytime bSBP (initial value) and age. In contrast, dipping of cSBP<sup>MAP/DBPcal</sup> was only weakly associated with dipping of heart rate. Therefore, we propose a new integrative model for bSBP dipping, stressing the role of heart rate dipping; whereas SBP at the aorta and central arteries exhibits no or only little decrease during nighttime, SBP dipping is exaggerated at the usual measuring site of BP, which is the brachial artery, in part, due to accompanying dipping in heart rate, because the difference between cSBP and bSBP (amplification) strongly depends on heart rate<sup>3,60</sup> (Figure S6). Although, when using the Mobilograph PWA device, we prefer the MAP/DBP calibration for several reasons, among them a better concordance with true invasive cSBP,<sup>16,21</sup> a closer relationship with hypertension-associated organ damage,<sup>23,29–31</sup> and a closer association with clinical endpoints<sup>25</sup>; it should be noted that a smaller dipping of SBP amplification was noted for cSBP<sup>SBP/DBPcal</sup> as well.

Our results have to be considered in the light of potential strengths and limitations. Among the strong points, we took advantage of the raw data of a worldwide large data set of measurements with a single device, which allows post hoc quality control, data harmonization, and recalculation of different methods for waveform calibration. Reassuring is also the fact that SBP amplification and its changes from daytime to nighttime have been observed with other devices<sup>61,62</sup> and calibration methods<sup>63,64</sup> as well, although the differences were not as pronounced as with our preferred MAP/DBP calibration method. One limitation is the fact that our results related to nighttime/daytime difference amplification are not yet based on clinical outcomes. Furthermore, based on previous recommendations,<sup>46</sup> we relied on fixed time intervals for definition of daytime and nighttime, rather than utilizing individual patient diaries. Although this is not expected to be a major limitation, the relevant results should be interpreted with this in mind. Finally, our findings, obtained with the Mobilograph device in all centers, cannot be necessarily generalized to other noninvasive central BP devices.

## PERSPECTIVES

We present reference values for ambulatory 24-hour cSBP from a worldwide research consortium. These thresholds need to be tested prospectively in longitudinal studies with clinical outcomes. Furthermore, we challenge the widely held view on nocturnal SBP dipping and propose that the nighttime fall in SBP is largely confined to the brachial artery, mediated to an important degree by the nighttime fall in heart rate. The physiological and pathological consequences should be further explored.

## ARTICLE INFORMATION

Received May 25, 2021; accepted September 26, 2021.

## Affiliations

Cardiology Department, Klinikum Wels-Grieskirchen, Austria (T.W., R.K.B., K.D.). Cardiovascular Prevention and Research Unit, Clinic-Laboratory of Pathophysiology and First Department of Propeadeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece (A.D.P., A.A., P.P.S.). Centre de Recherche Du CHU de Québec, Université Laval, Canada (M.A.). Lebanese American University School of Medicine, Byblos, Lebanon (S.A.B.). Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ and CIBER in Epidemiology and Public Health, Spain (J.R.B., J.J.C., A.G.). AP-HP Centre-Université de Paris, Hôpital Hôtel-Dieu, Centre de diagnostic et de thérapeutique, France (J.B., A.V.). State University of Rio de Janeiro, Brazil (A.A.B.). School of Medicine and Surgery, Milano-Bicocca University and Cardiology 4, ASST GOM Niguarda, Milan, Italy (C.G., A.M.). Austrian Institute of Technology, Vienna, Austria (B.H., C.C.M., S.W.). Institute of Cardiology, Jagellonian University, Krakow, Poland (P.J.). Centre for Vascular Evaluations, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (Y.L.). Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, United Kingdom (B.J.M.). Experimental Medicine and Immunotherapeutics, Addenbrooke's Hospital, University of Cambridge, United Kingdom (C.M.M., I.W.). Centro Universitario CESMAC, Alagoas, Brazil (M.A.M.G., A.M.G.). Department of Clinical and Experimental Sciences, Centro per la Prevenzione e Cura dell'ipertensione Arteriosa, University of Brescia and ASST Spedali Civili, Italy (M.L.M., A.P.). Department of Family Medicine, Semmelweis University, Budapest, Hungary (J.N.). Universidad Cardenal Herrera-CEU, CEU Universities, Hospital de Sagunto, Valencia, Spain (E.R.). School of Population Health, University of New South Wales, Sydney, Australia (A.E.S.). The George Institute for Global Health, Sydney, Australia (A.E.S.). Hypertension in Africa Research Team, SAMRC Unit for Hypertension and Cardiovascular Disease, North-West University, South Africa (A.E.S.). First Department of Cardiology, Hippokraton General Hospital, National and Kapodistrian University of Athens, Greece (D.T.-P., C.V.). SAMRC/Wits Developmental Pathways for Health Research Unit, South Africa (L.W.). DSI-NRF Centre of Excellence in Human Development, University of the Witwatersrand, South Africa (L.W.). Department of Cardiology, Medical University Graz, Austria (R.Z.). Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (J.E.S.).

## Acknowledgments

Sincere thanks are given to Brigitte Kupka at AIT for operating the central i24abc database.

## Sources of Funding

i24abc (International 24-Hour Ambulatory Aortic Blood Pressure Consortium) is a purely academic research project without industry funding. Funding of individual authors: J. Nemcsik was supported by the Hungarian Society of Hypertension; M. Agharazii was supported by the Canadian Institutes of Health Research; Y. Li is supported by grants from the National Natural Science Foundation (81770455 and 82070432) and the Ministry of Science and Technology, Beijing, China (2018YFC1704902); J.R. Banegas is supported by Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, and FEDER/FSE (grants PI16/01460 and PI19/00665); A. Maloberti and C. Giannatasio were supported by the Italian Ministry of University and Research (MIUR), Department of Excellence project PREMIA (PRECision Medicine Approach: bringing biomarker research to clinic); A.D. Protogerou's team has received unrestricted research grant and equipment support from IEM Stolberg.

## Disclosures

T. Weber has received research support from IEM, Stolberg, Germany, for a multicenter study; S. Wassertheurer and C.C. Mayer are inventors (not holders) of a patent that is used in the ARCSolver method; J. Blacher has received research support or has served on advisory boards or as a speaker for Abbott, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bouchara-Recordati, Daiichi Sankyo, Ferring, Gilead, Icomed, Medexact, Medtronic, Novartis, Novo Nordisk, Quantum Genomics, Saint Jude, Sanofi Aventis, and Servier; A.E. Schutte has received research support from IEM, Stolberg, Germany, in the form of devices; she also received speaker honoraria from Omron Healthcare, Novartis, Takeda, and Servier; J.E. Sharman university has received equipment and research funding from the manufacturers of BP devices including AtCor Medical, IEM, and Pulsecor (Uscom). He has no personal commercial interests related to BP companies. The other authors report no conflicts.

## REFERENCES

1. Pauca AL, Wallenhaupt SL, Kon ND, Tucker WY. Does radial artery pressure accurately reflect aortic pressure? *Chest*. 1992;102:1193–1198. doi: 10.1378/chest.102.4.1193



2. McEnery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. *Eur Heart J*. 2014;35:1719–1725. doi: 10.1093/eurheartj/ehu565
3. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P; Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. *Eur Heart J*. 2014;35:3122–3133. doi: 10.1093/eurheartj/ehu293
4. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: a consensus document. *Hypertension*. 2007;50:154–160. doi: 10.1161/HYPERTENSIONAHA.107.090068
5. Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. *Hypertension*. 2016;67:183–190. doi: 10.1161/HYPERTENSIONAHA.115.06066
6. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension*. 2007;50:197–203. doi: 10.1161/HYPERTENSIONAHA.107.089078
7. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, Masotti G, Roman MJ. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARE Dicomano Study. *J Am Coll Cardiol*. 2008;51:2432–2439. doi: 10.1016/j.jacc.2008.03.031
8. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? *J Hypertens*. 2009;27:461–467. doi: 10.1097/hjh.0b013e3283220ea4
9. Eguchi K, Miyashita H, Takenaka T, Tabara Y, Tomiyama H, Dohi Y, Hashimoto J, Ohkubo T, Ohta Y, Hirooka Y, et al. High central blood pressure is associated with incident cardiovascular events in treated hypertensives: the ABC-J II Study. *Hypertens Res*. 2018;41:947–956. doi: 10.1038/s41440-018-0075-8
10. Lamarche F, Agharazii M, Madore F, Goupil R. Prediction of cardiovascular events by type I central systolic blood pressure: a prospective study. *Hypertension*. 2021;77:319–327. doi: 10.1161/HYPERTENSIONAHA.120.16163
11. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006;113:1213–1225. doi: 10.1161/CIRCULATIONAHA.105.595496
12. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. *Hypertension*. 2010;55:1314–1322. doi: 10.1161/HYPERTENSIONAHA.109.148999
13. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. *Hypertension*. 2009;54:716–723. doi: 10.1161/HYPERTENSIONAHA.109.131466
14. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification. *Curr Pharm Des*. 2009;15:272–289. doi: 10.2174/138161209787354186
15. Sharman JE, Marwick TH, Gilroy D, Otahal P, Abhayaratna WP, Stowasser M; Value of Central Blood Pressure for GUIDing ManagEment of Hypertension Study Investigators. Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. *Hypertension*. 2013;62:1138–1145. doi: 10.1161/HYPERTENSIONAHA.113.02001
16. Papaioannou TG, Karageorgopoulou TD, Sergentanis TN, Protogerou AD, Psaltopoulou T, Sharman JE, Weber T, Blacher J, Daskalopoulou SS, Wassertheurer S, et al. Accuracy of commercial devices and methods for noninvasive estimation of aortic systolic blood pressure: a systematic review and meta-analysis of invasive validation studies. *J Hypertens*. 2016;34:1237–1248. doi: 10.1097/HJH.0000000000000921
17. Picone DS, Schultz MG, Otahal P, Akhsh S, Al-Jumaily AM, Black JA, Bos WJ, Chambers JB, Chen CH, Cheng HM, et al. Accuracy of cuff-measured blood pressure: systematic reviews and meta-analyses. *J Am Coll Cardiol*. 2017;70:572–586. doi: 10.1016/j.jacc.2017.05.064
18. Celler BG, Butlin M, Argha A, Tan I, Yong ASC, Avolio A. Are Korotkoff sounds reliable markers for accurate estimation of systolic and diastolic pressure using brachial cuff sphygmomanometry. *IEEE Trans Biomed Eng*. 2021. doi: 10.1109/TBME.2021.3079578
19. Sharman JE, Avolio AP, Baulmann J, Benetos A, Blacher J, Blizzard CL, Boutouyrie P, Chen CH, Chowieniczky P, Cockcroft JR, et al. Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. *Eur Heart J*. 2017;38:2805–2812. doi: 10.1093/eurheartj/ehw632
20. Picone DS, Schultz MG, Peng X, Black JA, Dwyer N, Roberts-Thomson P, Qasem A, Sharman JE. Intra-arterial analysis of the best calibration methods to estimate aortic blood pressure. *J Hypertens*. 2019;37:307–315. doi: 10.1097/HJH.0000000000001902
21. Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, Kropf J, Eber B. Validation of a brachial cuff-based method for estimating central systolic blood pressure. *Hypertension*. 2011;58:825–832. doi: 10.1161/HYPERTENSIONAHA.111.176313
22. Gotzmann M, Hogeweg M, Bauer F, Seibert FS, Rohn BJ, Mügge A, Babel N, Westhoff TH. The impact of calibration approaches on the accuracy of oscillometric central aortic blood pressure measurement. *J Hypertens*. 2020;38:2154–2160. doi: 10.1097/HJH.0000000000002563
23. Nakagomi A, Okada S, Shoji T, Kobayashi Y. Crucial effect of calibration methods on the association between central pulsatile indices and coronary atherosclerosis. *Am J Hypertens*. 2017;30:24–27. doi: 10.1093/ajh/hpw118
24. Negishi K, Yang H, Wang Y, Nolan MT, Negishi T, Pathan F, Marwick TH, Sharman JE. Importance of calibration method in central blood pressure for cardiac structural abnormalities. *Am J Hypertens*. 2016;29:1070–1076. doi: 10.1093/ajh/hpw039
25. Wassertheurer S, Baumann M. Assessment of systolic aortic pressure and its association to all cause mortality critically depends on waveform calibration. *J Hypertens*. 2015;33:1884–1888; discussion 1889. doi: 10.1097/HJH.0000000000000633
26. Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. *JAMA*. 2019;322:409–420. doi: 10.1001/jama.2019.9811
27. Topouchian J, Mourad JJ, De Champvallins M, Feldmann L, Asmar R; Study Coordinators, Investigators. Feasibility of 24-h central blood pressure monitoring: experience from multinational clinical trial assessing the efficacy of perindopril/indapamide/amlodipine. *J Hypertens*. 2019;37:2442–2451. doi: 10.1097/HJH.0000000000002199
28. Protogerou AD, Argyris A, Nasothimiou E, Vrachatis D, Papaioannou TG, Tzamouranis D, Blacher J, Safar ME, Sfikakis P, Stergiou GS. Feasibility and reproducibility of noninvasive 24-h ambulatory aortic blood pressure monitoring with a brachial cuff-based oscillometric device. *Am J Hypertens*. 2012;25:876–882. doi: 10.1038/ajh.2012.63
29. Weber T, Wassertheurer S, Schmidt-Trucksäss A, Rodilla E, Ablasser C, Jankowski P, Lorenza Muesan M, Giannattasio C, Mang C, Wilkinson I, et al. Relationship between 24-hour ambulatory central systolic blood pressure and left ventricular mass: a prospective multicenter study. *Hypertension*. 2017;70:1157–1164. doi: 10.1161/HYPERTENSIONAHA.117.09917
30. Protogerou AD, Argyris AA, Papaioannou TG, Kollias GE, Konstantonis GD, Nasothimiou E, Achimastos A, Blacher J, Safar ME, Sfikakis PP. Left-ventricular hypertrophy is associated better with 24-h aortic pressure than 24-h brachial pressure in hypertensive patients: the SAFAR study. *J Hypertens*. 2014;32:1805–1814. doi: 10.1097/HJH.0000000000000263
31. Zhang Y, Kollias G, Argyris AA, Papaioannou TG, Tountas C, Konstantonis GD, Achimastos A, Blacher J, Safar ME, Sfikakis PP, Protogerou AD. Association of left ventricular diastolic dysfunction with 24-h aortic ambulatory blood pressure: the SAFAR study. *J Hum Hypertens*. 2015;29:442–448. doi: 10.1038/jhh.2014.101
32. Argyris AA, Nasothimiou E, Aissopou E, Papaioannou TG, Zhang Y, Blacher J, Safar ME, Sfikakis PP, Protogerou AD. Mechanisms of pulse pressure amplification dipping pattern during sleep time: the SAFAR study. *J Am Soc Hypertens*. 2018;12:117–127. doi: 10.1016/j.jash.2017.12.005
33. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for

- ambulatory blood pressure monitoring. *J Hypertens*. 2014;32:1359–1366. doi: 10.1097/HJH.0000000000000221
34. Lauder L, Scholz SS, Ewen S, Lettner C, Ukena C, Böhm M, Mahfoud F. Accuracy of pulse rate derived from 24-h ambulatory blood pressure monitoring compared with heart rate from 24-h Holter-ECG. *J Hypertens*. 2020;38:2387–2392. doi: 10.1097/HJH.0000000000002566
  35. Jones CR, Taylor K, Chowieńczyk P, Poston L, Shennan AH. A validation of the Mobil O Graph (version 12) ambulatory blood pressure monitor. *Blood Press Monit*. 2000;5:233–238. doi: 10.1097/00126097-200008000-00007
  36. Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. *Blood Press Monit*. 2010;15:229–231. doi: 10.1097/mbp.0b013e328339be38
  37. Sarafidis PA, Lazaridis AA, Imprialos KP, Georgianos PI, Avranas KA, Protogerou AD, Doumas MN, Athyros VG, Karagiannis AI. A comparison study of brachial blood pressure recorded with Spacelabs 90217A and Mobil-O-Graph NG devices under static and ambulatory conditions. *J Hum Hypertens*. 2016;30:742–749. doi: 10.1038/jhh.2016.11
  38. Nakagomi A, Okada S, Shoji T, Kobayashi Y. Comparison of invasive and brachial cuff-based noninvasive measurements for the assessment of blood pressure amplification. *Hypertens Res*. 2017;40:237–242. doi: 10.1038/hr.2016.132
  39. Gotzmann M, Hogeweg M, Seibert FS, Rohn BJ, Bergbauer M, Babel N, Bauer F, Mügge A, Westhoff TH. Accuracy of fully automated oscillometric central aortic blood pressure measurement techniques. *J Hypertens*. 2020;38:235–242. doi: 10.1097/HJH.0000000000002237
  40. Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, Hametner B, Mayer CC, Eber B, Magometschnigg D. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. *J Hum Hypertens*. 2010;24:498–504. doi: 10.1038/jhh.2010.27
  41. Hoshida S, Komori T, Ogata Y, Eguchi K, Kario K. Evaluation of central blood pressure in an Asian population: comparison between brachial oscillometry and radial tonometry methods. *Pulse (Basel)*. 2018;6:98–102. doi: 10.1159/000484442
  42. Sánchez R, Pessana F, Lev G, Mirada M, Mendiz O, Ramírez A, Fischer EC. Central blood pressure waves assessment: a validation study of non-invasive aortic pressure measurement in human beings. *High Blood Press Cardiovasc Prev*. 2020;27:165–174. doi: 10.1007/s40292-020-00371-4
  43. Smulyan H, Sheehe PR, Safar ME. A preliminary evaluation of the mean arterial pressure as measured by cuff oscillometry. *Am J Hypertens*. 2008;21:166–171. doi: 10.1038/ajh.2007.45
  44. Head GA, Mihailidou AS, Duggan KA, Beilin LJ, Berry N, Brown MA, Bune AJ, Cowley D, Chalmers JP, Howe PR, et al; Ambulatory Blood Pressure Working Group of the High Blood Pressure Research Council of Australia. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. *BMJ*. 2010;340:c1104. doi: 10.1136/bmj.c1104
  45. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339
  46. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. *J Hypertens*. 2005;23:697–701. doi: 10.1097/01.jhh.0000163132.84890.c4
  47. Paiva AMG, Mota-Gomes MA, Brandão AA, Silveira FS, Silveira MS, Okawa RTP, Feitosa ADM, Sposito AC, Nadruz W Jr. Reference values of office central blood pressure, pulse wave velocity, and augmentation index recorded by means of the Mobil-O-Graph PWA monitor. *Hypertens Res*. 2020;43:1239–1248. doi: 10.1038/s41440-020-0490-5
  48. Cheng HM, Chuang SY, Sung SH, Yu WC, Pearson A, Lakatta EG, Pan WH, Chen CH. Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risk. *J Am Coll Cardiol*. 2013;62:1780–1787. doi: 10.1016/j.jacc.2013.06.029
  49. Wilkinson IB, McEniery CM, Cockcroft JR. Central blood pressure estimation for the masses moves a step closer. *J Hum Hypertens*. 2010;24:495–497. doi: 10.1038/jhh.2010.47
  50. Mitchell GF. Central pressure should not be used in clinical practice. *Artery Res*. 2015;9:8–13. doi: 10.1016/j.artres.2014.11.002
  51. Huang QF, Aparicio LS, Thijs L, Wei FF, Melgarejo JD, Cheng YB, Sheng CS, Yang WY, Gilis-Malinowska N, Boggia J, et al; IDCARS (International Database of Central Arterial Properties for Risk Stratification) Investigators. Cardiovascular end points and mortality are not closer associated with central than peripheral pulsatile blood pressure components. *Hypertension*. 2020;76:350–358. doi: 10.1161/HYPERTENSIONAHA.120.14787
  52. Wassertheurer S, Hametner B, Mayer CC, Hafez A, Negishi K, Papaioannou TG, Protogerou AD, Sharman JE, Weber T. Aortic systolic pressure derived with different calibration methods: associations to brachial systolic pressure in the general population. *Blood Press Monit*. 2018;23:134–140. doi: 10.1097/MBP.0000000000000319
  53. Littler WA, Honour AJ, Pugsley DJ, Sleight P. Continuous recording of direct arterial pressure in unrestricted patients. Its role in the diagnosis and management of high blood pressure. *Circulation*. 1975;51:1101–1106. doi: 10.1161/01.cir.51.6.1101
  54. Pickering TG, Harshfield GA, Kleinert HD, Blank S, Laragh JH. Blood pressure during normal daily activities, sleep, and exercise. Comparison of values in normal and hypertensive subjects. *JAMA*. 1982;247:992–996.
  55. Weir MR, Blantz RC. Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. *Curr Opin Nephrol Hypertens*. 2003;12:57–60. doi: 10.1097/00041552-200301000-00010
  56. Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. *Sleep Med Rev*. 2017;33:4–16. doi: 10.1016/j.smrv.2016.02.003
  57. Voogel AJ, Koopman MG, Hart AA, van Montfrans GA, Arisz L. Circadian rhythms in systemic hemodynamics and renal function in healthy subjects and patients with nephrotic syndrome. *Kidney Int*. 2001;59:1873–1880. doi: 10.1046/j.1523-1755.2001.0590051873.x
  58. Diamant M, Harms MP, Imminck RV, Van Lieshout JJ, Van Montfrans GA. Twenty-four-hour non-invasive monitoring of systemic haemodynamics and cerebral blood flow velocity in healthy humans. *Acta Physiol Scand*. 2002;175:1–9. doi: 10.1046/j.1365-201X.2002.00953.x
  59. Sindrup JH, Kastrup J, Christensen H, Jørgensen B. Nocturnal variations in peripheral blood flow, systemic blood pressure, and heart rate in humans. *Am J Physiol*. 1991;261(4 pt 2):H982–H988. doi: 10.1152/ajpheart.1991.261.4.H982
  60. Williams B, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. *J Am Coll Cardiol*. 2009;54:705–713. doi: 10.1016/j.jacc.2009.02.088
  61. Burns MJ, Seed JD, Incognito AV, Doherty CJ, Notay K, Millar PJ. Comparison of laboratory and ambulatory measures of central blood pressure and pulse wave reflection: hitting the target or missing the mark? *J Am Soc Hypertens*. 2018;12:275–284. doi: 10.1016/j.jash.2018.01.014
  62. Omboni S, Posokhov I, Parati G, Rogoza A, Kotovskaya Y, Arystan A, Avolio A, Barkan V, Bulanova N, Cardona Muñoz E, et al; VASOTENS Registry Study Group. Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry. *J Clin Hypertens (Greenwich)*. 2019;21:1155–1168. doi: 10.1111/jch.13623
  63. Williams B, Lacy PS, Baschiera F, Brunel P, Düsing R. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: the Ambulatory Central Aortic Pressure (AmCAP) study. *Hypertension*. 2013;61:1168–1176. doi: 10.1161/HYPERTENSIONAHA.111.00763
  64. Jankowski P, Bednarek A, Olszanecka A, Windak A, Kawecka-Jaszcz K, Czarnecka D. Twenty-four-hour profile of central blood pressure and central-to-peripheral systolic pressure amplification. *Am J Hypertens*. 2013;26:27–33. doi: 10.1093/ajh/hps030